Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Rana R. McKay, Marc R Radke, Yu Shyr, Shilin Zhao, Mary-Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard Joseph Appleman, Primo "Lucky" N. Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn Bubley, Ying Huang, Geoffrey Shapiro, Patricia LoRusso, S. Percy Ivy, Daniel Peter Petrylak, Elizabeth M. Swisher, Joseph W. Kim
Institutions: Moores Cancer Center, University of Washington Medical Center, Vanderbilt University Medical Center, Dana-Farber Cancer Institute, Vanderbilt University, Vanderbilt-Ingram Cancer Center, The Ohio State University, UPMC Health System, University of California System, University of Michigan, Moffitt Cancer Center, Virginia Commonwealth University Medical Center, Beth Israel Deaconess Medical Center, Yale University, National Institutes of Health, National Cancer Institute, University of Washington, Yale Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3133645156